Acyclovir/cytomegalovirus immune globulin combination therapy for CMV prophylaxis in high-risk renal allograft recipients.
Carrieri
G
G
University of Bari.
Jordan
M L
ML
Shapiro
R
R
Scantlebury
V P
VP
Vivas
C
C
Kusne
S
S
Magnone
M
M
McCauley
J
J
Starzl
T E
TE
D000212:Acyclovir / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000503:physiopathology / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control; D012086:Reoperation; D012307:Risk Factors; D013997:Time Factors; D014184:Transplantation, Homologous
D007136:Immunoglobulins; D007166:Immunosuppressive Agents; D000212:Acyclovir